WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. This report is updated annually.
This roadmap describes ten priorities, grouped into three core themes, that address the major health and economic impacts of zoonotic TB.
This report presents the findings of a short-term study to examine the risk of TB among health care workers. It discusses the possible effects of federal guidelines, responses to resurgent TB, and proposed strategies for eliminating TB in the United States and worldwide.
This report discusses ways to reduce the spread and impact of infectious diseases, such as the six most deadly: HIV/AIDS, pneumonia, diarrhea, malaria, measles, and TB.
This report provides findings from a study designed to compare a whole-blood interferon gamma assay, the QuantiFERON-TB test, with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection and to identify factors associated with discordance between the tests.
This report presents information about the Global TB Drug Facility, a program designed to ensure access to and the availability of TB drugs.
This report discusses the global efforts of national education and advocacy events that occurred on World Tuberculosis (TB) Day 2002. The report provides information about campaigns that promoted TB prevention through socioeconomic change, government support, the formation of partnerships between governments and nongovernmental organizations (NGOs), and improved healthcare access and delivery.
This report, updated annually, details the global epidemiology of TB based on the data supplied by the national TB programs from WHO member states.
This report outlines a strategy for management of human resources for TB control.
This prospectus is a culmination of input from Stop TB Partners including representatives from TB high-burden countries, UN agencies, Nongovernmental Organizations (NGOs), and foundations to develop the form, strategies, objectives, and governance of the Global TB Drug Facility (GDF).
